
A chronic obstructive pulmonary disease (COPD) study reveals one moderate exacerbation is enough to merit an escalation in COPD therapy, impacting morbidity and mortality. Global Initiative for Chronic Obstructive Lung Disease (GOLD) emphasizes assessing symptoms and exacerbations for COPD classification. The study showed that 13.3% of Category A and 18.2% of Category B patients had one steroid-treated exacerbation the previous year. Mortality in Category E, with COPD hospitalization, was the highest.
Like
Save
Share